Desmopressin for Bleeding Related to Low Body Temperature

Phase 4UnknownNCT00902057

The University of Hong Kong48 enrolled

Overview

To study, with a prospective randomised controlled design, whether the subcutaneous administration of the haemostatic drug desmopressin, may improve the impairment of primary haemostasis due to mildly decreased temperature.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Hypothermia Induced Impairment of Primary Haemostasis

Interventions

desmopressinDRUG

single desmopressin subcutaneous injection, 1.5mcg

desmopressinDRUG

single desmopressin subcutaneous injection, 3mcg

desmopressinDRUG

single desmopressin subcutaneous injection, 15mcg

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1\. Healthy volunteers Exclusion Criteria: 1. Any known platelet or coagulation disorder. 2. Pregnant or lactating women. 3. Known chronic liver or renal disease. 4. Coronary artery, carotid artery or peripheral artery disease 5. Recent history of taking antiplatelet drugs, anticoagulants or herbal preparations. 6. Smoker or alcohol user 7. Mentally incapable of providing informed consent 8. Students or junior staff members who had direct working relationship with the PI

Locations (1)

The University of Hong Kong

Hong Kong, Hong Kong, China

Outcomes

Primary Outcomes

closure time on PFA-100

Time frame: 3 hours

Central Contacts

Kwok F.J. Ng, MBChB, MD, MBA, FANZCA, FHKAM

CONTACT

(852) 28553303 jkfng@hku.hk

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.